Zamora-Ortiz G, Morales-Floranes R, Velázquez-Sánchez-de-Cima S, García-Villaseñor A, Ruiz-Argüelles GJ

Language: Spanish
References: 11
Page: 120-123
PDF size: 320.52 Kb.

ABSTRACT

Background: Several variables influence the prognosis of patients after hematopoietic stem cell transplantation (HSCT), but there are discrepancies in the results of different studies that include gender as a prognosis factor.
Objective: To determine the role of gender as a prognostic factor in overall survival (OS) post HSCT.
Material and methods: Retrospective study of 285 patients undergoing HSCT between January 1993 and September 2012 in the Clínica Ruiz de Puebla. Results: In the period indicated, 155 allogeneic transplants were done, 40% female and 60% male, diagnosed with acute myelogenous leukemia (AML) in 25%, acute lymphoblastic leukemia (ALL) in 23%, chronic mielogenous leukemia (CML) in 19%. The OS, in women, was 38% at 131 months and 35% at 155 months, in men. In the same period, 130 autologous transplants were performed, 48% female and 52% male, diagnosed with multiple myeloma in 38%, ALL in 17%, AML in 15%. The OS was 58% at 214 months in women, and 65% at 229 months, in men. The OS was calculated according to the Kaplan Meier method and linear regression was performed analyzing OS with gender, age, body mass index and underlying diagnosis basis, obtaining R2 of 0.0335. T test was performed for gender and OS, without statistical significance.
Conclusions: In this study, which included autologous and allogeneic transplants, regardless of age or diagnsosis, there was no statistically significant difference in terms of gender in the OS post HSCT.

REFERENCES

1. Ruiz-Argüelles GJ. Whither the bone marrow transplant. Hematology 2010;15:1-3.

2. Miel CM, Martin PJ, Leisenring W, et al. Graft-versus-hostdisease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102: 756-762.

3. Bacigalupo A. Third EBMT/AMGEN workshop on reducedintensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004;33:691-696.

4. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leuk. Lymphoma 2004;45:1191-1195.

5. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Morales E. Trasplante de células progenitoras hematopoyéticas. En: Góngora-Biachi R. (editor) Hematología: Actualización 2004. México: Agrupación Mexicana para el Estudio de la Hematología, Mérida, 2004;139-148.

6. Ruiz-Argüelles GJ. Historia del trasplante de médula ósea en México. Rev Hematol Méx 2004;5:80-85.

7. Arcese W, Goldman JM, D’Arcangelo E, Schattenberg A, Nardi A, Apperley JF, et al. Outcome for patients who relapse after allogenic bone marrow transplantation for chronic myeloid leukemia. Blood FALTA;82:3211-3219.

8. Gahrton G, Iacobelli S, Apperley J, Bandini G, Bladé J, Boiron JM, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant 2005;35:609-617.

9. Harvey J, Green A, Cornish J, Steward C, Cummins M, Keen L, et al. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II. Bone Marrow Transplantation 2012;47:1294-1300.

10. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, et al. Allogenic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009;114:2060-2067.

11. Locatelli F, Nölke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomnocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;:410-419.